drugset / Trial / NCT05585151
High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study
Phase 4
Unknown
200 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RandomizedParallel-groupOpen-labelTreatment
Summary
This study intends to explore the therapeutic effect of PCSK9i Evolocumab on atherosclerotic plaques in cerebral arteries (including carotid and vertebral arteries) compared with intensive statin treatment, and monitor the pathological properties of carotid/vertebral artery plaques with OCT technology. At the same time, three-dimensional ultrasound and high-resolution magnetic resonance are used to explore the new mechanism of pathological changes of cerebral atherosclerotic plaques in a multidimensional manner.
Timeline
- Start
- 2022-11-09
- Primary completion
- 2024-04-01
- Completion
- 2024-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atorvastatin | Small molecule | 40 mg | — |
| Subject | Evolocumab | Monoclonal antibody | 140 mg | Subcutaneous |
| Comparator | Rosuvastatin | Small molecule | 20 mg | — |